Palmar‐plantar erythrodysesthesia syndrome following treatment with high‐dose methotrexate or high‐dose cytarabine
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30762
Abstract: Palmar‐plantar erythrodysesthesia syndrome (PPES) is an uncommon side effect of high‐dose cytarabine or methotrexate. Prior case reports of PPES have been limited, and the predisposing factors for the development of PPES remain unknown. read more here.
Keywords: plantar erythrodysesthesia; palmar plantar; high dose; dose cytarabine ... See more keywords
Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia research"
DOI: 10.1016/j.leukres.2017.06.007
Abstract: Cytarabine (Ara-c) has been an important agent in acute myeloid leukemia (AML) treatment for more than 40 years. While, the mechanisms underlying low dose cytarabine (LD Ara-c) is poorly understood. In this study, we investigated… read more here.
Keywords: low dose; myeloid leukemia; treatment; dose cytarabine ... See more keywords
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyab112
Abstract: Abstract Background In a multinational phase 3 trial (VIALE-C), venetoclax plus low-dose cytarabine prolonged overall survival vs placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy, although it… read more here.
Keywords: low dose; dose cytarabine; venetoclax plus; plus low ... See more keywords
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Sign Up to like & getrecommendations! Published in 2023 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyad027
Abstract: BACKGROUND In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who were… read more here.
Keywords: dose cytarabine; acute myeloid; plus low; study ... See more keywords
Acute cerebellar toxicity induced by high dose of cytarabine (HiDAC): A case report
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155219898747
Abstract: Cytarabine is a pyrimidine analogue that is used for the treatment of acute myeloid leukemia at different doses. Standard doses of cytarabine are used for induction therapy, while high doses are used for post-remission (consolidation)… read more here.
Keywords: acute cerebellar; high dose; dose cytarabine; cerebellar toxicity ... See more keywords
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2018018945
Abstract: Approximately 5% to 10% of children with Down syndrome (DS) are diagnosed with transient myeloproliferative disorder (TMD). Approximately 20% of these patients die within 6 months (early death), and another 20% to 30% progress to… read more here.
Keywords: low dose; myeloid leukemia; dose cytarabine; tmd ... See more keywords
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Oncotarget"
DOI: 10.18632/oncotarget.27618
Abstract: A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage… read more here.
Keywords: high dose; myeloid leukemia; dose cytarabine; cytarabine mitoxantrone ... See more keywords
Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Sign Up to like & getrecommendations! Published in 2021 at "Annals of palliative medicine"
DOI: 10.21037/apm-19-379
Abstract: Acute myeloid leukemia (AML) is a malignant clonal hematopoietic stem cell disease. Although there are many therapeutic options, it is still an incurable hematological malignancy. Moreover, the prognosis of AML is closely related to its… read more here.
Keywords: decitabine combined; dose cytarabine; dek; medium dose ... See more keywords
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.242826
Abstract: Recent clinical data have shown a synergistic effect of venetoclax in combination with the hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with incomplete cell count recovery [CRi]: 73%, median overall survival [OS] of… read more here.
Keywords: low dose; combination hypomethylating; myeloid leukemia; dose cytarabine ... See more keywords
Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2020.267526
Abstract: The outcome of acute myeloid leukemia (AML) is affected by disease characteristics as well as treatment regimens. In the CALGB8525 trial, patients with core binding factor (CBF)-positive leukemia benefited from consolidation with a high dose… read more here.
Keywords: intermediate dose; transplantation; dose cytarabine; group ... See more keywords